arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Pharma Pricing and Value Summit

Forging the Future of Market Access

New York |
Speakers include:
Doug Ingram

Doug Ingram

Sarepta Therapeutics

Mariângela Simão

Mariângela Simão

World Health Organization

Chip Davis

Chip Davis

Association for Accessible Medicines

Overview

The pharmaceutical pricing and market access landscape is being transformed by a host of factors. Value-based pricing is making the transition from concept to reality but more clarity is needed on what it means and how it works for different stakeholders. Revolutionary therapies with innovative pricing models are entering the market but at the same time decision-makers at pharma companies are being asked to defend pricing strategies for established products. Meanwhile, much of the US government's blueprint to lower drug prices is still in the works and yet to be enacted.  

The FT Pharma Pricing and Value Summit will explore the future of drug pricing from a balanced perspective. How could the rebate system evolve? Will new powers for Medicare Part D to negotiate drug prices really make a difference to patients?  What global factors could change the pricing and market access landscape in the US? 

Join us in New York on September 26, 2019 to engage with and learn from the full spectrum of pricing and market access stakeholders including pharma companies, insurers, PBMs, employers, providers and patients. 

fallback
fallback Add to my Calendar 09/26/2019 08:00:0009/26/2019 17:00:00trueFT Pharma Pricing and Value SummitThe pharmaceutical pricing and market access landscape is being transformed by a host of factors. Value-based pricing is making the transition from concept to reality but more clarity is needed on what it means and how it works for different stakeholders. Revolutionary therapies with innovative pricing models are entering the market but at the same time decision-makers at pharma companies are being asked to defend pricing strategies for established products. Meanwhile, much of the US government's blueprint to lower drug prices is still in the works and yet to be enacted.  The FT Pharma Pricing and Value Summit will explore the future of drug pricing from a balanced perspective. How could the rebate system evolve? Will new powers for Medicare Part D to negotiate drug prices really make a difference to patients?  What global factors could change the pricing and market access landscape in the US? Join us in New York on September 26, 2019 to engage with and learn from the full spectrum of pricing and market access stakeholders including pharma companies, insurers, PBMs, employers, providers and patients. FT-Pharma-Pricing-and-Value-Summit886f4d407b12c673119f1bf4f40497bfMM/DD/YYYY

2018 Photos

View the 2018 event photos here.

29952997847_2b053460d5_z

fallback

Speakers (19)

Doug Ingram

Doug Ingram

President and Chief Executive Officer
Sarepta Therapeutics

Douglas S. Ingram has served as Sarepta Therapeutics President, Chief Executive Officer and a member of the Board since June 2017. Prior to his appointment, from December 2015 until November 2016, he served as the Chief Executive Officer and President and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Mr Ingram served as the President of Allergan from July 2013 until it was acquired by Actavis in early 2015. At Allergan, he also served as President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010, where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr Ingram also served as General Counsel of Allergan from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. Mr Ingram received his Juris Doctor from the University of Arizona and his Bachelor of Science degree from Arizona State University. He is a board member for Relay Therapeutics.

Mariângela Simão

Mariângela Simão

Assistant Director-General, Access to Medicines, Vaccines and Pharmaceuticals
World Health Organization

Mariângela Simão joined the World Health Organization in November 2017, as part of Dr Tedros Adhanom Ghebreyesus’ leadership team. She previously worked for UNAIDS since September 2010 and prior to that, she worked for the Ministry of Health in Brazil as the Director of the Sexually Transmitted Diseases, HIV/ AIDS and Viral Hepatitis department. She worked in the Brazilian public health system since 1982, from the primary health care level to a series of managerial positions throughout the years. As a public health professional, at municipal, state and national levels, she played an active role in the decentralization of the national health system, acquiring an extensive experience in health system strengthening. She has also served on the boards of a number of organizations and government committees related to public health and HIV. Heading the National Sexually Transmitted Diseases/HIV/AIDS Department (including Viral Hepatitis from 2009), she had the responsibility of overseeing and implementing the national Sexually Transmitted Diseases/AIDS/Viral Hepatitis policies, including universal and free of charge access to treatment, care and comprehensive prevention programs. Dr Simão attended medical school in Brazil, with degrees in Paediatrics and Public Health, and a MSc in Mother and Child Health in the UK.

Chip Davis

Chip Davis

President and Chief Executive Officer
Association for Accessible Medicines

Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Appointed to the position by the AAM Board in summer 2015, Chip is responsible for ensuring that the association fulfils its primary mission, which is to improve the lives of patients and consumers by providing timely access to safe, effective and affordable medicines. Prior to joining AAM, Chip most recently served as Executive Vice President for Advocacy and Member Relations at the Pharmaceutical Research and Manufacturers of America (PhRMA), where he was responsible for leading PhRMA’s federal, state and international government relations and advocacy efforts, in addition to member company recruitment and retention. Prior to joining PhRMA, he was Vice President of Corporate External Relations for AstraZeneca, where he oversaw the company’s government relations, strategic alliances, community relations and employee volunteer efforts. He was a member of AstraZeneca’s Corporate Affairs Leadership team and Vice Chairman of the company’s Political Action Committee. In 2007, Chip was one of the inaugural winners of the AstraZeneca CEO Award, given to global executives who best demonstrate AstraZeneca leadership capabilities in their accomplishments. Chip earned an undergraduate degree in Accounting from the University of Delaware, and a Juris Doctor from the University of Baltimore School of Law. He is a licensed attorney in Maryland, Virginia and the District of Columbia. He currently serves on the board of directors for the Washington, D.C. area Chapter of Autism Speaks, the University of Delaware Alumni Association and the St. Mary’s High School Royal Blue Club, and the member advisory board for the National Journal.

Gerard Anderson

Gerard Anderson

Professor of Health Policy and Management
Johns Hopkins Bloomberg School of Public Health and Medicine

Gerard Anderson is a professor of health policy and management, international health and medicine and the director of the Johns Hopkins Center for Hospital Finance and Management. Prior to coming to Johns Hopkins in 1983, Dr Anderson worked in the Office of the Secretary of the US Department of Health and Human Services from 1978 to 1983. Dr Anderson is currently conducting research on drug pricing, chronic conditions, comparative insurance systems, medical education, health care payment reform, and technology diffusion. He has directed over 100 research projects; authored two books on health care payment policy, published 300 peer-reviewed articles, testified in Congress 50 times, and serves on multiple editorial committees.

Jenny Bryant

Jenny Bryant

Senior Vice President, Policy and Research
PhRMA

Jenny Bryant serves as Senior Vice President, Policy and Research for the Pharmaceutical Research and Manufacturers of America (PhRMA), the national association representing the country’s leading pharmaceutical research and biotechnology companies. At PhRMA, she oversees analysis and development of public policy related to health care costs and spending, prescription drug pricing, and changes in health care delivery and payment. She manages a broad portfolio of economic and policy research, with a focus on better understanding how medicines are used and valued, and the impact of appropriate medication use on health care costs. Prior to joining PhRMA, Jenny was Vice President at The Lewin Group, a national health care consulting firm. Previously, she held positions at Blue Cross Blue Shield Association, Blue Cross Blue Shield of Florida, New York Hospital-Cornell Medical Center, and the State of New York. Jenny graduated magna cum laude from Harvard College and received her MBA from the Harvard Graduate School of Business Administration.

Tony Barrueta

Tony Barrueta

Senior Vice President of Government Relations
Kaiser Permanente

Tony Barrueta is Senior Vice President of Government Relations for Kaiser Foundation Health Plan, Inc. and Hospitals. He is responsible for guiding the development of Kaiser Permanente's public policy positions and leading Government Relations teams in Oakland, Sacramento, and Washington, D.C. Since 1994, Tony has held several positions in Kaiser Permanente’s Government Relations department including Vice President, Senior Counsel, and Counsel. Previously, he was in private law practice in Washington, D.C. Tony received his undergraduate degree from Boston College and his law degree from the University of Texas at Austin. He is licensed to practice law in California and the District of Columbia.

Mike Cloonan

Mike Cloonan

Chief Business Officer
Sage Therapeutics

Mike is the architect of the Sage commercial organization behind the launch of company’s first product, ZULRESSO™ (brexanolone) injection CIV, and is guiding the strategy for potential commercialization of future innovative treatments that emerge from Sage’s deep portfolio focused on brain health.  He joined Sage as Chief Business Officer in April 2017 and leads the Commercial, Portfolio and Program Management, Medical Affairs, Government Affairs, and Corporate Development departments. Previously, he served as Senior Vice President, US Commercial, at Biogen where he led the US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. Mike’s 14-year tenure at Biogen included roles as Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia/New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, he worked at Bain & Company as a consultant specializing in healthcare. Mike earned his MBA from Darden Graduate School of Business Administration, University of Virginia and a BA from College of the Holy Cross.

Sarah Emond

Sarah Emond

Executive Vice President and Chief Operating Officer
Institute for Clinical and Economic Review (ICER)

Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review (ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.
Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy. She also received a Bachelor’s degree in Biological Sciences from Smith College.

Robert Dubois

Robert Dubois

Chief Science Officer and Executive Vice President
National Pharmaceutical Council (NPC)

Robert W. Dubois, MD, PhD, is the Chief Science Officer and Executive Vice President of the National Pharmaceutical Council (NPC). In this role, he oversees NPC’s research on policy issues related to the appropriate role of real-world evidence in decision-making, how best to determine value of health care services, the relationship between access and health outcomes, and approaches to maintain an environment supportive of innovation. Dr Dubois, who is board-certified in internal medicine, brings more than 25 years of experience in health care research, with a particular focus on understanding and ensuring that patients receive high value health care. He has co-founded and led various health care research organizations in developing quality research with practical application. Dr Dubois was previously the Chief Medical Officer of Cerner Life Sciences, co-founded Protocare Sciences and was its Executive Vice President, Chief Medical Officer, and later its CEO. Throughout his career, Dr Dubois’ primary interest has centered on defining “what works” in health care and finding ways for that evidence to inform health care decision-making. He is a recognized expert in the areas of defining best practice, disease management and appropriateness of care. He has authored more than 175 peer-reviewed articles on comparative effectiveness, evidence-based medicine, the development of practice guidelines and determining the optimal use of high-cost medical services. Dr Dubois received his AB from Harvard College, his MD from the Johns Hopkins School of Medicine and his PhD in health policy from the RAND Graduate School. He is the Associate Editor of the Journal of Comparative Effectiveness Research and is on the editorial board for Health Affairs and The American Journal of Managed Care.

Chris Easley

Chris Easley

Managing Director
Huron Life Sciences Practice

Chris Easley has over 17 years’ experience in consulting for the pharmaceutical industry with experience spanning P&R and commercial strategy. He leads a broad range of market access and pricing projects at Huron in both product-related MA strategy work as well as MA planning, process and organizational capability building projects. He has particular expertise in value proposition development, including the implications for payer evidence development and integration with cross functional brand plans, as well as expertise in innovative contracting solutions. Chris has had exposure to many therapeutic areas over his career, including issues around pricing and access for rare diseases, as well as in-depth knowledge of oncology and cardiovascular/metabolic disease areas.

Yvonne Greenstreet

Yvonne Greenstreet

Chief Operating Officer
Alnylam

Yvonne Greenstreet has over 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management. She has successfully led product development and commercialisation teams in a wide range of therapy areas, and bringing new medicines to patients. Dr Greenstreet was previously Senior Vice President and Head of Medicines Development at Pfizer, and a member of the executive team for the specialty business, with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, she held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe. Dr Greenstreet received her medical degree (MBChB) from the University of Leeds, UK, and an MBA degree from INSEAD, France. She serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, and Indivior PLC, a global specialty pharmaceutical business. Dr Greenstreet also serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation.

Anna Kaltenboeck

Anna Kaltenboeck

Senior Health Economist and Program Director, Center for Health Policy and Outcomes
Memorial Sloan Kettering Cancer Center

Anna Kaltenboeck is a Senior Health Economist and the Program Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. Her work focuses on the development and application of value-based pricing methods, as well as policies that foster rational and sustainable drug pricing. Prior to joining MSKCC, Anna spent 10 years consulting on health economics and outcomes research, as well as pricing and market access for pharmaceutical and diagnostic products. An alumna of both Analysis Group and IMS Consulting Group, the scope of her work spans the US, EU5, and emerging economies. She has published numerous articles in peer-reviewed scientific and policy journals. Anna holds bachelor’s and master’s degrees in economics from Tufts University.

Chris Leibman

Chris Leibman

Senior Vice President, Value and Access
Biogen

Chris Leibman is Senior Vice President, Value and Access at Biogen, where he leads the global value demonstration, access and pricing strategy development and execution across the Biogen portfolio. Prior to this role Chris lived in Zug, Switzerland where he led market access and pricing at Biogen for Europe and Canada. Chris joined Biogen in 2014 from Janssen Pharmaceuticals, where he served as head of Market Access and Policy: Neuroscience and led the team responsible for the development and execution of market access strategies and value evidence generation across the neuroscience franchise. Prior to this, first with Élan Pharmaceuticals and then with Janssen AI following their program acquisition, Chris led the market access launch readiness activities across the Alzheimer Immunotherapy Program in partnership with Pfizer. Chris has published and presented extensively on the benefits and costs of prescription drugs in Alzheimer’s disease, value frameworks in healthcare, and sustainable pricing in drug development. He brings two decades of diverse experiences in biopharmaceutical development, value demonstration, access, and working across multi-company alliances. Chris holds a B.S. degree in biology, from the University of Illinois at Urbana-Champaign and Doctor of Pharmacy from the University of Illinois at Chicago. Following his pharmacy degree, he completed a post-doc fellowship in health economics with GlaxoWellcome and earned a M.S. degree with focus in pharmacoeconomics and health policy from the Ohio State University.

David Merritt

David Merritt

Executive Vice President of Public Affairs and Strategic Initiatives
America’s Health Insurance Plans (AHIP)

David Merritt is Executive Vice President of Public Affairs and Strategic Initiatives at America’s Health Insurance Plans (AHIP). He leads AHIP’s communications and coalitions, advocacy and strategy on issues ranging from Medicare and Medicaid to health policy, value, and prescription drug costs. He has a proven track record in policy, politics, and press. He was a Managing Director for Frank Luntz at Luntz Global Partners, one of America’s best known and most respected public opinion and strategic communication shops, leading the firm’s political and policy strategy and research. Previously, he was Partner and Managing Director at Leavitt Partners, the healthcare consulting firm led by former HHS Secretary and Utah Governor Mike Leavitt. He led the firm’s Washington, DC office, advising clients on a wide range of issues, including the Affordable Care Act and Washington politics. He was the leading fundraiser and a presidential campaign adviser to former Speaker of the House Newt Gingrich. He worked closely with Speaker Gingrich for more than seven years, including as CEO of the Center for Health Transformation. He was also a health policy adviser to the 2008 presidential campaigns of Senator John McCain and former Senator Fred Thompson. 

Tom Rice

Tom Rice

Vice President, US RAV & Payer Strategy
Amgen

Tom is the Vice President of US Reimbursement Value & Access and Payer Strategy for Amgen Inc. His team is charged with setting the strategic direction for market access across Amgen’s entire portfolio. A 12-year veteran at Amgen, he recently served as Executive Director of the Cardiovascular RAV team including the flagship product Repatha®. Tom’s 25+ years of industry experience also includes Product Marketing, New Product Commercialization, Sales Management, Managed Care Marketing, Sales Analytics, Institutional and Field Sales at Aventis and its predecessor companies. He holds an undergraduate degree in Marketing from the University of Wisconsin-Milwaukee and an MBA from the University of Kansas. Tom has served as an Adjunct Professor in the Master of Science Program in Healthcare Decision Analysis at the USC School of Pharmacy.

Chuck Stevens

Chuck Stevens

Vice President, Access, Commercialization and Communications
ICON plc

Charles A. Stevens, JD, MBA is the Vice President of the Access, Commercialisation and Communications practice at ICON.  This global service has over 300 life science consultants who support the commercial success of drugs, devices and diagnostics. Prior to joining ICON, Chuck spent nine years at PAREXEL as the Vice President and General Manager of Reimbursement and Market Access, and held positions of increasing responsibility at Abbott Laboratories, Genetics Institute, Wyeth Oncology, Cell Therapeutics and Cephalon Oncology. He has significant experience in leading pricing, payer strategy, channel management, pharmacoeconomic modeling, government price reporting, payer marketing, patient advocacy and dossier development for products across many disease states, including hematology, oncology, infectious disease and rare disorders. Chuck has worked on issues involving the Affordable Care Act (ACA), the Medicare Modernization Act (MMA) of 2003, the Single Drug Pricer (SDP) system and obtaining product specific HCPCS codes. He was a member of a bio-pharmaceutical consortium that successfully advocated for CMS expansion of recognized drug compendia supporting reimbursement and patient access to therapy in oncology.  Chuck is a past member of the government affairs committee of NASP (National Association of Specialty Pharmacies), ISPOR’s (International Society for Pharmacoeconomics and Outcomes Research) Institutional Council and its CER (Comparative Effectiveness Research) Workgroup.

Rick Suarez

Rick Suarez

Senior Vice President, US Market Access
AstraZeneca

Rick R. Suarez is Senior Vice President, US Market Access at AstraZeneca where he leads teams responsible for securing patient access to AstraZeneca medicines in collaboration with national and regional payers, distributors, retailers, wholesalers and Group Purchasing Organizations (GPOs).  Rick’s teams are also responsible for reimbursement support and one of the longest-standing patient assistance programs in the industry. He has nearly two decades of diverse experience in healthcare leading teams aligned to Sales, Marketing, and Market Access, including heading up the NEXIUM franchise. He holds a BS in Chemistry and Sociology from the University of N. Alabama. Rick brings unique perspective on the external environment and the move towards greater focus on value-based payment. Under his leadership, AstraZeneca has emerged as an industry leader in value-based agreements.

Kathleen Tregoning

Kathleen Tregoning

Executive Vice President, External Affairs
Sanofi

As the Executive Vice President for External Affairs at Sanofi, Kathleen serves on the 15-person Executive Management Committee, driving the strategic direction for a global biopharmaceutical company with €34 billion in annual sales, business operations in 100 countries, and treatments spanning specialty medicines, rare diseases, primary care, vaccines, and consumer health products. Kathleen is responsible for leading Sanofi’s unique, integrated External Affairs organization, bringing together market access, communications, public policy, government affairs, patient advocacy, and corporate social responsibility. She oversees 1,500 employees in a global, matrixed organization. Kathleen’s strategic leadership harnesses the collective strengths and capabilities of her team to enhance the company’s reputation, engage proactively to shape the policy environment, optimize patient access to therapies, and achieve business objectives. She has worked and lived abroad, building upon her extensive knowledge of the U.S. market with direct experience in Europe, Japan, Canada, China, and India. Prior to joining Sanofi, Kathleen spent more than 10 years at Biogen, first as Vice President, Public Policy & Government Affairs, and then as Senior Vice President, Corporate Affairs. In the latter role, she had responsibility for the development and execution of integrated corporate affairs strategies through effective deployment of communications, patient advocacy, public policy, and government affairs on a global basis. Kathleen worked as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee. She began her career with Andersen Consulting, where she developed business strategies and processes for clients in a range of industries, including health care. She later served as an Assistant Deputy Mayor for Policy & Budget in the office of the Mayor of Los Angeles. Kathleen graduated from Stanford University with a degree in International Relations, holds a graduate degree in Public Policy from the Harvard Kennedy School, and completed an Executive Development Program at The Wharton School. She is a 5-time marathon finisher, an avid reader, and a member of the Paris Choral Society. Kathleen currently lives in Paris with her husband and two children. 

Mark Trusheim

Mark Trusheim

Strategic Director, NEWDIGS
MIT Center for Biomedical Innovation

Mark Trusheim is Strategic Director, MIT NEWDIGS where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project; and a Visiting Scientist at the MIT Sloan School of Management. Through MIT he has also served as a Special Government Employee for the FDA’s Office of the Commissioner. Mr Trusheim’s research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials and digital health advances. Prior to MIT, his career spanned big data at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics, and policy as the President of the Massachusetts Biotechnology Council. He holds degrees in Chemistry from Stanford University and Management from MIT.

fallback

Chair and moderators (2)

Sarah Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. 

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Agenda - 26th Sep

  • 8:00am
    Breakfast and Registration
  • 9:00am
    Opening Remarks

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:10am
    Panel: Pricing Pressures for 2020 and Beyond
    • What impact is President Trump’s Blueprint to Lower Drug Prices having?
    • What healthcare reforms are being proposed by 2020 presidential candidates and how could they affect drug prices?
    • How real is the shift towards value-based pricing?
    • What changes are we seeing across the global pricing and market access landscape?
    • Does reference pricing have a future in the US?

    Chip Davis, President and Chief Executive Officer, Association for Accessible Medicines 

    Anna Kaltenboeck, Senior Health Economist and Program Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

    Mark Trusheim, Strategic Director, MIT NEWDIGS, MIT Center for Biomedical Innovation

    Rick Suarez, Senior Vice President, US Market Access, AstraZeneca

    Moderated by Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:55am
    New Business Models to Support Innovation in Payer Partnerships

    As emerging healthcare innovations demand alternative – and often more sophisticated – approaches to negotiating access and price, companies are looking at how best to support the building of necessary internal skills, capabilities and ways of working.

    Chris Easley, Managing Director, Huron Life Sciences Practice

  • 10:15am
    Fireside Chat: Evolving Medicine Payments and Reimbursement

    Today’s medicines, including one-time curative treatments, harness the very latest scientific advances, but is our current health care system structured to handle this innovation? What is it going to take to evolve the payment and reimbursement system to keep up with the science and assure patient access?

    Jenny Bryant, Senior Vice President, Policy and Research, PhRMA

    Interviewed by Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 10:35am
    Morning Refreshments
  • 11:05am
    Panel: Bringing Advanced Therapies to Market
    • How do you value a cure with a one-time treatment?
    • How do you develop sustainable pricing and market access strategies for orphan drugs?
    • Should value be defined primarily by the cost-offset or by patient outcomes?
    • How can real-world evidence accelerate market access for advanced therapies? 
    • How are digital therapeutics being brought to market?
    • How can pharma work with other stakeholders to maximize access to gene therapies?

    Mike Cloonan, Chief Business Officer, Sage Therapeutics

    Yvonne Greenstreet, Chief Operating Officer, Alnylam

    Doug Ingram, President and Chief Executive Officer, Sarepta Therapeutics

    Tom Rice, Vice President, US RAV & Payer Strategy, Amgen

    Moderated by Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times

  • 11:50am
    Industry Analysis: Payer Reliance on ICER, Global HTA Reviews and Providers to Determine Value and Coverage Policy

    With drug pricing a headline topic, determining product value can be challenging for payers, providers, policy makers and patient consumers. This session will present updated original research on US payers’ views on ICER assessments and ex-US HTA reviews, and new research results from 100 oncology nurses on drug/treatment value and patient access challenges.

    Chuck Stevens, Vice President, Access, Commercialization and Communications, ICON plc

  • 12:10pm
    Debate: The Future of Value Evaluation Frameworks in the US

    As the influence of organizations such as ICER grows, alternative approaches to assessing cost-effectiveness are becoming more credible. Should the process be more standardized and how are criteria decided?

    Robert Dubois, Chief Science Officer and Executive Vice President, National Pharmaceutical Council (NPC)

    Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER)

    Moderated by Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times

  • 12:50pm
    Networking Lunch
  • 1:50pm
    Fireside Chat: Improving Affordability of Prescription Drugs

    Hear how one of America's leading not-for-profit health care providers is driving down prescription drug costs for patients and employers.

    Tony Barrueta, Senior Vice President of Government Relations, Kaiser Permanente

    Interviewed by Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 2:20pm
    Ensuring Patient Advocacy Groups Are Accountable to Patients

    Patient Advocacy Organizations should be transparent in their funding so that patients and policy makers can be assured that their recommendations are in the best interest of their patients they represent.

    Gerard Anderson, Professor of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health and Medicine

  • 2:35pm
    Audience Polling Session

    This session will ask the audience several key questions on pricing and market access, and a panel will discuss the results.

    • Who is most to blame for high drug prices in the US?
    • Is drug pricing in the US becoming more transparent?
    • Is "global freeloading" a key reason for higher drug prices in the US?
    • Is increased influence of ICER a good thing for the US healthcare system?

    Gerard Anderson, Professor of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health and Medicine

    Chris Leibman, Senior Vice President, Value and Access, Biogen

    David Merritt, Executive Vice President of Public Affairs and Strategic Initiatives, America’s Health Insurance Plans (AHIP)

    Kathleen Tregoning, Executive Vice President, External Affairs, Sanofi

    Moderated by Hannah Kuchler, US Pharma and Biotech Correspondent, Financial Times

  • 3:20pm
    Realizing the Full Value of Medicines through Affordable Pricing: A Global Perspective

    Medicines are global goods when they are safe, effective and reach patients. But unaffordable prices prevent the full value of medicines from being realized. Interlinked underlying problems include: market failure, non-transparent markets, lack of optimal regulations, inefficient R&D. Hear what the WHO is doing to tackle the problem and how industry could play a critical role.

    Mariângela Simão, Assistant Director-General, Access to Medicines, Vaccines and Pharmaceuticals, World Health Organization

  • 3:50pm
    Closing Remarks

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 4:00pm
    Networking Drinks Reception

Who will be there?

FT Live has a reputation for delivering very senior, board-level audiences to attend a wide range of world-class thought-leadership events across the globe for nearly 40 years.

The FT Pharma Pricing and Value Summit will be attended by:

  • Pharmaceutical companies
  • Pharmacy benefit managers
  • Medical device manufacturers
  • Healthcare providers and insurers
  • Patient representatives and NGOs
fallback

Attending Companies

Sanofi • Novartis • Pfizer, Inc. • Novo Nordisk • Acadia Pharmaceuticals • Merck & Co., Inc. • Alnylam Pharmaceuticals • Pennsylvania Governor’s Advisory Commission on Asian Pacific American Affairs • Neurotez Inc. • National Pharmaceutical Council • Eisai • Sandoz • Sanofi US Service Inc. • Biogen • Bausch Health • CONTINUUS Pharmaceuticals • Ibex Biosciences, LLC • Bessor Pharma • ISPOR • Amarin Pharma, Inc. • Access To Medicine Foundation • Kaiser Permanente • Aetion, Inc., and many others.

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Founding Partner (1)

Life science companies face a rapidly evolving landscape, leading to strategic opportunities as well as challenges including the threat of disruption. Huron's life science practice is part of Huron’s continuum of healthcare offerings supporting the development and commercialization of pharmaceutical products and services.

At Huron, we work with life science companies who typically focus on:

  • Developing winning strategies and new innovative business models that go beyond individual assets and capabilities 
  • Building value and making a difference to all stakeholders throughout the healthcare continuum
  • Achieving affordable access to therapies while managing uncertainty around underlying data
  • Harnessing the power of new technologies and approaches such as digital solutions, use of real-world evidence and analytics, and companion diagnostics

Discover how Huron can help you to harness new developments and stay ahead of the curve. 

Corporate and Business Unit Strategy
Research and Development Portfolio Strategy
Market Access and Pricing
Transaction Support and Due Diligence
Asset Commercial Strategy
Organization and Innovation Development
Drug Safety and Regulatory
Digital Solutions and Technology

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

Lead Sponsor (1)

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.

Associate Sponsor (1)

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
 
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Supporting Partners (2)

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based biopharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. Follow us on Twitter @npcnow.

PharmaBoardroom is the premier website for C-Level executives, regulators, consultants and vendors working in Healthcare Life Sciences globally. PharmaBoardroom gathers the data, the people and the opinions that matter, and makes market synergies meet. With hundreds of exclusive interviews with shakers and movers of the industry, supplemented by the latest news from global markets, articles, market overviews, and a comprehensive database of the most important companies and business leaders in each key market, PharmaBoardroom is an invaluable resource for those who want to look beyond figures. 

Contacts

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Ciaran Larkin
Content Manager
Financial Times Live
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times

Venue

Stewart Hotel
371 Seventh Ave (between W 30th and W 31th Sts)
New York 10001

United States of America


fallback

Accommodation

  • Take advantage of the exclusive rates available for our delegates at the Stewart Hotel. Make your reservation now via this link to take advantage of this offer.

Stwart Hotel New York

  • We have put together a unique Hotel Map that shows hotel deals close to the event venue. To view the options click here.
fallback